Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Expression of concern Free access | 10.1172/JCI8707EX1

HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV-1 replication and cell death

Scott J. Brodie, Bruce K. Patterson, Deborah A. Lewinsohn, Kurt Diem, David Spach, Phillip D. Greenberg, Stanley R. Riddell, and Lawrence Corey

Find articles by Brodie, S. in: PubMed | Google Scholar

Find articles by Patterson, B. in: PubMed | Google Scholar

Find articles by Lewinsohn, D. in: PubMed | Google Scholar

Find articles by Diem, K. in: PubMed | Google Scholar

Find articles by Spach, D. in: PubMed | Google Scholar

Find articles by Greenberg, P. in: PubMed | Google Scholar

Find articles by Riddell, S. in: PubMed | Google Scholar

Find articles by Corey, L. in: PubMed | Google Scholar

Published May 1, 2008 - More info

Published in Volume 118, Issue 5 on May 1, 2008
J Clin Invest. 2008;118(5):1974–1974. https://doi.org/10.1172/JCI8707EX1.
© 2008 The American Society for Clinical Investigation
Published May 1, 2008 - Version history
View PDF

Related article:

HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death
Scott J. Brodie, … , Stanley R. Riddell, Lawrence Corey
Scott J. Brodie, … , Stanley R. Riddell, Lawrence Corey
Article

HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death

  • Text
  • PDF
Abstract

We have tracked the in vivo migration and have identified in vivo correlates of cytotoxic T-lymphocyte (CTL) activity in HIV-seropositive subjects infused with autologous gene-marked CD8+ HIV-specific CTL. The number of circulating gene-marked CTL ranged from 1.6 to 3.5% shortly after infusion to less than 0.5% 2 weeks later. Gene-marked CTL were present in the lymph node at 4.5- to 11-fold excess and colocalized within parafollicular regions of the lymph node adjacent to cells expressing HIV tat fusion transcripts, a correlate of virus replication. The CTL clones expressed the CCR5 receptor and localized among HIV-infected cells expressing the ligands MIP-1α and MIP-1β, CC-chemokines produced at sites of virus replication. Aggregates of apoptotic cells and cells expressing granzyme-B localized within these same sites. In contrast, lymph node sections from untreated HIV-seropositive subjects, all with significant viral burden (> 50,000 HIV RNA copies/mL plasma), showed no CC-chemokine expression and exhibited only sporadic and randomly distributed cells expressing granzymes and/or apoptotic cells. These studies show that the infused CTL specifically migrate to sites of HIV replication and retain their antigen-specific cytolytic potential. Moreover, these studies provide a methodology that will facilitate studies of both the magnitude and functional phenotype of Ag-specific CD8+ T cells in vivo.

Authors

Scott J. Brodie, Bruce K. Patterson, Deborah A. Lewinsohn, Kurt Diem, David Spach, Phillip D. Greenberg, Stanley R. Riddell, Lawrence Corey

×

Original citation: J. Clin. Invest.105:1407–1417 (2000). doi:10.1172/JCI8707.

Citation for this expression of concern: J. Clin. Invest.118:1974 (2008). doi:10.1172/JCI8707EX1.

In the issue of May 15, 2000, we published a study by Scott J. Brodie and colleagues. According to the report issued by John T. Slattery, Vice Dean of Research and Graduate Education at the University of Washington in Seattle, Washington, “Dr. Brodie was found to have falsified images that appeared as Figure 5A in the publication. These images respectively appeared in JCI as representing neomycin gene–marked CD8+ cells before patient infusions, with neo-positive cells showing yellow-red fluorescence and neo-negative cells being purple-blue; in one unfunded NIH grant application labeled as cells harboring HIV DNA (PCR in situ hybridization for gag DNA); and in a second unfunded NIH grant application as depicting alveolar macrophages from HIV+ persons treated with LPS, tuberculin or HIV tat protein-stain for viral RNA. The University’s investigative committee concluded that two or more of these images was falsified.”

There is an ongoing investigation into potential scientific misconduct in the performance of this study, reportedly by the Office of Research Integrity. We will inform our readers of the outcome of this investigation when it is complete.

Version history
  • Version 1 (May 1, 2008): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts